Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.140
-0.030 (-2.56%)
At close: Feb 13, 2026, 4:00 PM EST
1.150
+0.010 (0.88%)
After-hours: Feb 13, 2026, 7:34 PM EST
Jasper Therapeutics Employees
Jasper Therapeutics had 27 employees as of September 30, 2025. The number of employees decreased by 37 or -57.81% compared to the same quarter last year.
Employees
27
Change
-37
Growth
-57.81%
Revenue / Employee
n/a
Profits / Employee
-$3,371,148
Market Cap
31.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 27 | -37 | -57.81% |
| Dec 31, 2024 | 64 | 19 | 42.22% |
| Dec 31, 2023 | 45 | 10 | 28.57% |
| Dec 31, 2022 | 35 | 10 | 40.00% |
| Sep 30, 2022 | 36 | 14 | 63.64% |
| Jun 30, 2022 | 35 | 11 | 45.83% |
| Mar 31, 2022 | 34 | 12 | 54.55% |
| Dec 31, 2021 | 25 | 3 | 13.64% |
| Sep 30, 2021 | 22 | - | - |
| Jun 30, 2021 | 24 | - | - |
| Mar 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Atara Biotherapeutics | 38 |
| Actinium Pharmaceuticals | 25 |
| Tempest Therapeutics | 21 |
| Outlook Therapeutics | 17 |
| NeuroSense Therapeutics | 17 |
| Atossa Therapeutics | 15 |
| Hyperion DeFi | 14 |
JSPR News
- 5 weeks ago - Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript - Seeking Alpha
- 5 weeks ago - Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewsWire
- 5 weeks ago - Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - GlobeNewsWire
- 2 months ago - Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript - Seeking Alpha
- 2 months ago - Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - GlobeNewsWire
- 2 months ago - Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - GlobeNewsWire
- 2 months ago - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 3 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - Newsfile Corp